IFN-γ-deficient mice develop IL-1-dependent cutaneous and musculoskeletal inflammation during experimental brucellosis.

Jerod A Skyberg, Theresa Thornburg, Irina Kochetkova, William Layton, Gayle Callis, MaryClare F Rollins, Carol Riccardi, Todd Becker, Sarah Golden, David W Pascual
Author Information
  1. Jerod A Skyberg: Department of Immunology and Infectious Diseases, Montana State University, Bozeman, Montana, USA.

Abstract

Human brucellosis exhibits diverse pathological manifestations that can affect almost any organ. In particular, osteoarticular complications are the most common focal manifestation of brucellosis and occur in 40-80% of patients. In immunocompetent mice, Brucella replication is generally restricted to the spleen, liver, and to a lesser extent, LNs, thereby limiting their use for study of focal inflammation often found in brucellosis. Here, we report that nasal, oral, or peritoneal infection of IFN-γ(-/-) mice with WT Brucella melitensis or Brucella abortus results in joint and periarticular tissue inflammation. Histological analysis of the affected joints revealed inflammatory infiltrates and debris within the joint space colocalizing with Brucella antigen. Osteoarthritis, necrosis, periarticular soft tissue inflammation, and substantial brucellae burdens were observed. Oral rifampicin was effective in clearing infection and halting further progression of focal inflammation from infected IFN-γ(-/-) mice, although some symptoms and swelling remained. Elevated IL-1 β, but not TNF-α, IL-6, or IL-17, was detected in joint homogenates from infected IFN-γ(-/-) mice. Whereas more susceptible to systemic infection, IL-1R(-/-) mice depleted of IFN-γ were more resistant to focal inflammation than WT mice similarly depleted of IFN-γ. Collectively, these results show IFN-γ(-/-) mice represent a potential model for study of focal inflammation attributed to Brucella infection and will allow evaluation of intervention strategies targeting IL-1, IL-1R, or other inflammatory mediators, with the potential to complement antibiotic-based therapies.

References

  1. Korean J Intern Med. 2009 Dec;24(4):397-401 [PMID: 19949742]
  2. Clin Infect Dis. 1995 May;20(5):1241-9 [PMID: 7620005]
  3. Infect Immun. 2003 Jun;71(6):3437-42 [PMID: 12761128]
  4. Rheumatol Int. 2005 Jan;25(1):69-71 [PMID: 15007623]
  5. Lancet Infect Dis. 2006 Feb;6(2):91-9 [PMID: 16439329]
  6. Infect Immun. 2004 Aug;72(8):4891-4 [PMID: 15271956]
  7. Infect Immun. 2011 Oct;79(10):4165-74 [PMID: 21768283]
  8. J Clin Microbiol. 1999 Nov;37(11):3437-42 [PMID: 10523530]
  9. Clin Immunol. 2005 Mar;114(3):227-38 [PMID: 15721833]
  10. Infect Immun. 1999 Sep;67(9):4545-50 [PMID: 10456898]
  11. Immunology. 2001 Aug;103(4):511-8 [PMID: 11529943]
  12. Saudi Med J. 2002 Aug;23(8):921-4 [PMID: 12235463]
  13. Best Pract Res Clin Rheumatol. 2006 Oct;20(5):879-96 [PMID: 16980212]
  14. Nihon Seikeigeka Gakkai Zasshi. 1989 Nov;63(11):1343-52 [PMID: 2614163]
  15. Clin Infect Dis. 2008 Feb 1;46(3):426-33 [PMID: 18181740]
  16. J Rheumatol. 1989 Jun;16(6):800-6 [PMID: 2789287]
  17. J Infect Dis. 1994 Nov;170(5):1216-23 [PMID: 7963716]
  18. Int J Dermatol. 2001 Jul;40(7):434-8 [PMID: 11678996]
  19. Asian Pac J Allergy Immunol. 1998 Dec;16(4):155-60 [PMID: 10219896]
  20. Eur J Clin Microbiol Infect Dis. 1999 Aug;18(8):535-8 [PMID: 10517189]
  21. Ann Rheum Dis. 1990 Nov;49(11):896-900 [PMID: 2256735]
  22. Ann Microbiol (Paris). 1980 Nov-Dec;131B(3):277-87 [PMID: 7469256]
  23. Radiographics. 1994 Mar;14(2):333-48 [PMID: 8190957]
  24. J Immunol. 2008 Jul 15;181(2):954-68 [PMID: 18606647]
  25. J Immunol. 1998 Dec 1;161(11):5937-42 [PMID: 9834074]
  26. J Med Microbiol. 2010 Dec;59(Pt 12):1514-1518 [PMID: 20724508]
  27. Intern Med. 2008;47(23):2091-3 [PMID: 19043268]
  28. J Am Board Fam Pract. 2002 Sep-Oct;15(5):401-6 [PMID: 12350062]
  29. J Rheumatol. 2009 Dec;36(12):2846-7 [PMID: 19966198]
  30. Histol Histopathol. 2008 May;23(5):573-81 [PMID: 18283642]
  31. Am J Trop Med Hyg. 1999 Sep;61(3):425-7 [PMID: 10497984]
  32. Infect Immun. 2009 Mar;77(3):984-95 [PMID: 19103778]
  33. J Vet Diagn Invest. 1994 Jan;6(1):56-61 [PMID: 8011783]
  34. Infect Immun. 2002 Aug;70(8):4273-81 [PMID: 12117936]
  35. Clin Invest Med. 2001 Oct;24(5):250-7 [PMID: 11603509]
  36. J Immunol. 2003 Nov 1;171(9):4717-25 [PMID: 14568947]
  37. Mediators Inflamm. 2009;2009:394021 [PMID: 19606256]
  38. Thorax. 1996 Dec;51(12):1253-61 [PMID: 8994525]
  39. Adv Ther. 2007 Jul-Aug;24(4):706-11 [PMID: 17901020]
  40. Lancet. 1993 Jan 16;341(8838):146-8 [PMID: 8093746]
  41. Am J Reprod Immunol. 2005 Dec;54(6):358-68 [PMID: 16305661]
  42. J Immunol. 2008 Aug 15;181(4):2741-52 [PMID: 18684965]
  43. Clin Exp Rheumatol. 1999 Nov-Dec;17(6 Suppl 18):S105-14 [PMID: 10589368]
  44. Swiss Med Wkly. 2002 Feb 23;132(7-8):98-105 [PMID: 11971204]
  45. Arthritis Rheum. 2010 Nov;62(11):3237-48 [PMID: 20662061]
  46. Emerg Infect Dis. 1997 Apr-Jun;3(2):213-21 [PMID: 9204307]
  47. J Immunol. 2001 Jul 15;167(2):1004-13 [PMID: 11441109]
  48. JAMA. 2006 May 17;295(19):2275-85 [PMID: 16705109]
  49. Clin Vaccine Immunol. 2009 May;16(5):779-83 [PMID: 19321692]
  50. Biochem Biophys Res Commun. 2010 May 28;396(2):440-4 [PMID: 20433810]
  51. Int J Infect Dis. 2002 Sep;6(3):182-6 [PMID: 12718832]
  52. FEMS Immunol Med Microbiol. 2008 Jul;53(2):265-74 [PMID: 18522647]
  53. J Chemother. 2008 Feb;20(1):58-62 [PMID: 18343745]
  54. Croat Med J. 2004 Dec;45(6):727-33 [PMID: 15578807]
  55. Eur Radiol. 2004 Mar;14 Suppl 3:E64-71 [PMID: 14749954]
  56. Cell Microbiol. 2005 Oct;7(10):1459-73 [PMID: 16153245]
  57. J Infect. 2006 Nov;53(5):315-24 [PMID: 16488475]
  58. J Am Med Assoc. 1949 Oct 1;141(5):320-5 [PMID: 18140650]
  59. Pak J Biol Sci. 2010 Nov 1;13(21):1036-41 [PMID: 21313874]
  60. Semin Arthritis Rheum. 1982 Nov;12(2):245-55 [PMID: 6101216]
  61. Infect Immun. 1993 Jan;61(1):124-34 [PMID: 8418034]
  62. Scand J Rheumatol. 1986;15(4):377-80 [PMID: 3823795]
  63. PLoS One. 2011;6(7):e21978 [PMID: 21765931]
  64. Ann Rheum Dis. 1991 Jan;50(1):23-6 [PMID: 1994863]
  65. Infect Immun. 1991 May;59(5):1790-4 [PMID: 2019442]
  66. J Infect Dis. 2001 Oct 1;184(7):853-60 [PMID: 11509997]
  67. Int J Surg. 2008 Aug;6(4):328-38 [PMID: 17720643]
  68. J Immunol. 2010 Jun 15;184(12):7144-53 [PMID: 20483737]
  69. Infect Immun. 2009 Oct;77(10):4197-208 [PMID: 19651862]
  70. Infect Immun. 2011 Nov;79(11):4688-95 [PMID: 21844234]
  71. J Immunol. 2003 Dec 1;171(11):6173-7 [PMID: 14634133]
  72. J Virol. 1999 Jan;73(1):783-6 [PMID: 9847388]
  73. Eur J Immunol. 2004 Sep;34(9):2356-64 [PMID: 15307168]
  74. PLoS Pathog. 2010 Dec 09;6(12):e1001222 [PMID: 21170303]
  75. J Clin Microbiol. 2002 Oct;40(10):3878 [PMID: 12354908]
  76. Baillieres Clin Rheumatol. 1995 Feb;9(1):161-77 [PMID: 7728879]
  77. J Immunol. 2007 Feb 1;178(3):1791-9 [PMID: 17237429]
  78. Biochem Biophys Res Commun. 2004 Oct 22;323(3):979-86 [PMID: 15381096]

Grants

  1. P20 RR020185/NCRR NIH HHS

MeSH Term

Animals
Brucellosis
Cells, Cultured
Dermatitis
Disease Models, Animal
Humans
Inflammation
Inflammation Mediators
Interferon-gamma
Interleukin-1
Mice
Mice, Inbred BALB C
Mice, Inbred C57BL
Mice, Knockout
Myositis
Rabbits

Chemicals

Inflammation Mediators
Interleukin-1
Interferon-gamma

Word Cloud

Created with Highcharts 10.0.0miceinflammationIFN-γfocalBrucella-/-brucellosisinfectionjointstudyWTresultsperiarticulartissueinflammatoryinfectedIL-1IL-1RdepletedpotentialHumanexhibitsdiversepathologicalmanifestationscanaffectalmostorganparticularosteoarticularcomplicationscommonmanifestationoccur40-80%patientsimmunocompetentreplicationgenerallyrestrictedspleenliverlesserextentLNstherebylimitinguseoftenfoundreportnasaloralperitonealmelitensisabortusHistologicalanalysisaffectedjointsrevealedinfiltratesdebriswithinspacecolocalizingantigenOsteoarthritisnecrosissoftsubstantialbrucellaeburdensobservedOralrifampicineffectiveclearinghaltingprogressionalthoughsymptomsswellingremainedElevatedβTNF-αIL-6IL-17detectedhomogenatesWhereassusceptiblesystemicresistantsimilarlyCollectivelyshowrepresentmodelattributedwillallowevaluationinterventionstrategiestargetingmediatorscomplementantibiotic-basedtherapiesIFN-γ-deficientdevelopIL-1-dependentcutaneousmusculoskeletalexperimental

Similar Articles

Cited By